Please assess the completion status of the following clinical trial:

Trial Title: Food Effect on Pharmacokinetic Parameters of ABX464

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Caucasian male subjects, 18-55 years of age~* Body Mass Index (BMI) of 17-28 kg/m².~* Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination)~* Normal vital signs after 10 minutes resting in supine position:~  90 mmHg \< systolic blood pressure \< 140 mmHg, 50 mmHg \< diastolic blood pressure \< 90 mmHg, 40 bpm \< heart rate \< 100 bpm.~* Normal automatic 12-lead ECG (incomplete right bundle branch block can be accepted) or judged as non clinically significant.~* Clinical laboratory tests (hematology, blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to Investigator and Sponsor.~* Subjects must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules.~Exclusion Criteria:~* Individuals with a history of any significant medical disorder which requires a physician's care (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease; any acute infectious disease or signs of acute illness)~* Frequent headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month).~* Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician.~* Individuals who have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to drug administration.~* Any individual who does not comply with the requirement that he should not have used any drugs other than paracetamol for at least 2 weeks prior to the study nor alcohol within 48 hours prior to drug administration.~* Individuals who are positive for hepatitis B virus, hepatitis C virus or HIV.~* History or presence of drug or alcohol abuse (positive urine drug screen, positive alcohol breath test).~* Smoking more than 5 cigarettes or equivalent / day, unable to stop smoking during the study.~* Excessive consumption of beverages with xanthine bases (\> 4 cups or glasses / day).~* Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time.~* Individuals who have donated blood within the preceding 3 months.~* Individuals who refuse to use an effective method of contraception from the beginning of the study and until 3 months after dosing.~* Individuals with forfeiture of freedom by an administrative or legal obligation or under guardianship

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Fasted Conditions (Type: EXPERIMENTAL): 50mg of ABX464 (two 25mg capsules) /Fasted
- Fed Conditions (Type: EXPERIMENTAL): 50mg of ABX464 (two 25mg capsules) /Fed

Based on this trial design, predict the completion outcome and termination type (if applicable).